Sign in to view content

Assessing Commercially Available Cell Therapies for Retinal Disease in the U.S.

Ajay E Kuriyan, MD, MS
Daniel Simhaee, MD

Video
Published 2018

Related

Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
Jared S. Nielsen, MD, MBA
Updates from the Field
2022
Therapies for Diabetic Macular Edema: What’s in the Pipeline?
Peter K. Kaiser, MD FASRS
Updates from the Field
2018
The Evolving Treatment of Proliferative Diabetic Retinopathy: The Diabetic Retinopathy Study to the DRCR Protocol S
Timothy W. Olsen, MD
Webinars and Journal Clubs
2016

Category: Hereditary Retinal Disease & Genetics

See more